Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Ochre Bio logo —

Ochre Bio

Founded 2019 United Kingdom Oxford, United Kingdom 60 employees Series A Total: $39.88M Biotechnology, Pharmaceutical

General Information

Company Name Ochre Bio
Founded Year 2019
Location United Kingdom Oxford, United Kingdom +2
Employees 60
Industries Biotechnology, Pharmaceutical
Funding Stage Series A
Social

Get notified when Ochre Bio moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

AI Insight

Bounce Watch AI
2 months ago

Ochre Bio's recent engagement, with a key team member participating in a podcast to discuss strategies for securing investment, indicates a proactive approach to investor relations. This suggests the company is strategically positioning itself for future capital raises. Building on its recent Series A funding, this move highlights the importance of sustained capital injection for advancing its RNA therapy pipeline in chronic liver diseases.

Signal Types
Funding Event Participation
Strategic Labels
Fundraising Strategy Investor Relations
Next Move: Fundraising
·
Impact: 6/10
·
Ideal For: Biotech VCs — Series B / Growth Stage

About Ochre Bio

Ochre Bio is a dynamic biotechnology company founded in 2019 in the United Kingdom. Specializing in the development of RNA therapies for chronic liver diseases, the company leverages genomic deep phenotyping and precision RNA medicine.

Ochre Bio's innovative approach involves testing therapies in live human donor livers, highlighting their commitment to advancing liver health solutions. By focusing on increasing donor liver supply and reducing cirrhosis complications, they address pressing healthcare challenges in the biotechnology and pharmaceutical industries.

Recently, the company secured a Series A investment on 01 October 2023, with contributions from investors such as Gaingels and STCAP. This funding will likely bolster Ochre Bio's research efforts and facilitate the continued development of groundbreaking RNA therapies for liver disease.

Taxonomy: RNA Therapies, Chronic Liver Diseases, Genomic Deep Phenotyping, Precision Medicine, Transplant Enhancement, Liver Rejuvenation, Genomics, Liver Health, Cirrhosis Complications, Advanced Therapies, Liver Genomics Research, Biotech Innovation

Services & Products

Development of RNA therapies
AI-driven drug discovery
Human liver data integration
Validation in human liver models

Target Customers

Pharmaceutical companies Biotech researchers Medical institutions focusing on liver diseases Investors in advanced biotech innovations

Funding Rounds & Investors (6)

View All
Funding Stage Amount Investors Lead Investors Date
Series A •••••• 2
Investor Investor
01 Oct 2023
Series A •••••• 11
Investor Investor Investor Investor Investor Investor Investor
•••• •••• 		01 Oct 2022
Series A •••••• 2
Investor Investor
01 Dec 2021
Seed •••••• 6
Investor Investor Investor Investor Investor Investor
01 Jun 2021
Seed •••••• 1
Investor
01 Aug 2020

View All 6 Funding Rounds

Ochre Bio Alternatives & Competitors

View All Alternatives
Ochre Bio vs
HepaRegeniX GmbH
HepaRegeniX GmbH Germany

Unlocking liver regeneration - delivering recovery

Unknown
15 employees
Biotechnology, Health Care
Compare Ochre Bio vs HepaRegeniX GmbH
Ochre Bio vs
CymaBay Therapeutics
CymaBay Therapeutics United States

Dedicated to improving the lives of patients with liver diseases

Acquired
32 employees
Biopharma, Biotechnology
Compare Ochre Bio vs CymaBay Therapeutics
Ochre Bio vs
Vital Therapies
Vital Therapies

Pioneering the future of liver therapy with innovative cell-based treatments for acute liver failure...

Private Equity
Biotechnology, Health Care
Compare Ochre Bio vs Vital Therapies
View all alternatives

FAQ About Ochre Bio

Ochre Bio was founded in 2019.
Ochre Bio is headquartered in Oxford, United Kingdom.
Ochre Bio operates in the following industries: Biotechnology, Pharmaceutical.
Ochre Bio has approximately 60 employees.
Ochre Bio has completed 6 funding rounds, raising a total of $39.88M. The latest funding stage is Series A.
Ochre Bio offers: Development of RNA therapies, AI-driven drug discovery, Human liver data integration, Validation in human liver models.
Top alternatives and competitors to Ochre Bio include HepaRegeniX GmbH, CymaBay Therapeutics, Vital Therapies, Aligos Therapeutics, Intercept Pharmaceuticals. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Ochre Bio and HepaRegeniX GmbH are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Ochre Bio and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy